朱雨荷,熊华龙,张天英

• 1:厦门大学国家传染病诊断试剂与疫苗工程技术研究中心
• 2:厦门大学分子疫苗学和分子诊断学国家重点实验室
• 3:厦门大学公共卫生学院

摘要(Abstract)：

病毒载体广泛应用于传染病疫苗研发，基于水泡性口炎病毒载体的埃博拉疫苗和多款基于腺病毒载体的新型冠状病毒疫苗已获批上市。其中水泡性口炎病毒具有易培养、安全高效、无整合风险、受人体预存免疫影响低、能刺激机体产生高强度细胞和体液免疫反应等优势，因此成为最有前景的病毒载体之一。本综述对重组水泡性口炎病毒载体的疫苗构建、应用以及面临的挑战和未来研究方向进行总结，为深入研究基于水泡性口炎病毒载体疫苗的提供了参考，也为新发突发传染病的防治提供新的策略和建议。

关键词(KeyWords)： 水泡性口炎病毒;病毒载体疫苗;改造策略

Abstract:

Keywords:

基金项目(Foundation): 福建省自然科学基金杰出青年项目（项目号：2020J06007）题目：β属冠状病毒B亚群广谱中和表位鉴定及其在疫苗和抗体研发中的应用~~

作者(Author): 朱雨荷,熊华龙,张天英

DOI: 10.13242/j.cnki.bingduxuebao.004372

参考文献(References)：

• [1] Whitt M A. Generation of VSV pseudotypes using recombinantΔG-VSV for studies on virus entry,identification of entry inhibitors, and immune responses to vaccines[J/OL]. J Virol Methods, 2010, 169(2):365–374. DOI:10.1016/j.jviromet.2010.08.006.
• [2] Lay Mendoza, M F, Acciani M D, Levit C N, Santa Maria C, Brindley M A. Monitoring viral entry in realtime using a luciferase recombinant vesicular stomatitis virus producing SARS-CoV-2, EBOV, LASV,CHIKV, and VSV glycoproteins[J/OL]. Viruses,2020, 12(12):E1457. DOI:10.3390/v12121457.
• [3] Li H, Zhao C, Zhang Y, Yuan F, Zhang Q, Shi X,Zhang L, Qin C, Zheng A. Establishment of replicationcompetent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays[J/OL]. Emerging Microbes Infect, 2020, 9(1):2269–2277. DOI:10.1080/22221751.2020.1830715.
• [4] Chen S T, Iida A, Guo L, Friedmann T, Yee J K.Generation of packaging cell lines for pseudotyped retroviral vectors of the G protein of vesicular stomatitis virus by using a modified tetracycline inducible system[J/OL]. Proc Natl Acad Sci U S A, 1996, 93(19):10057–10062. DOI:10.1073/pnas.93.19.10057.
• [5] Hug P, Sleight R G. Fusogenic virosomes prepared by partitioning of vesicular stomatitis virus G protein into preformed vesicles[J/OL]. J Biol Chem, 1994, 269(6):4050–4056.
• [6] Schnell M J, Buonocore L, Kretzschmar E, Johnson E,Rose J K. Foreign glycoproteins expressed from recombinant vesicular stomatitis viruses are incorporated efficiently into virus particles[J/OL]. Proc Natl Acad Sci U S A, 1996, 93(21):11359–11365. DOI:10.1073/pnas.93.21.11359.
• [7] Dieterle M E, Haslwanter D, Bortz R H, Wirchnianski A S, Lasso G, Vergnolle O, Abbasi S A, Fels J M,Laudermilch E, Florez C, Mengotto A, Kimmel D,Malonis R J, Georgiev G, Quiroz J, Barnhill J, Pirofski L A, Daily J P, Dye J M, Lai J R, Herbert A S,Chandran K, Jangra R K. A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2spike-mediated cell entry and its inhibition[J/OL]. Cell Host Microbe, 2020, 28(3):486-496. e6. DOI:10.1016/j.chom.2020.06.020.
• [8] Rose J, Schubert M(1987). Rhabdovirus Genomes and Their Products[EB/OL].(1987)[2023-02-21] https：//doi.org/10.1007/978-1-4684-7032-1_4
• [9] Blumberg B M, Leppert M, Kolakofsky D. Interaction of VSV leader RNA and nucleocapsid protein may control VSV genome replication[J/OL]. Cell, 1981, 23(3):837–845. DOI:10.1016/0092-8674(81)90448-7.
• [10]Green T J, Macpherson S, Qiu S, Lebowitz J, Wertz G W, Luo M. Study of the assembly of vesicular stomatitis virus N protein:role of the P protein[J/OL].J Virol, 2000, 74(20):9515–9524. DOI:10.1128/jvi.74.20.9515-9524.2000.
• [11]Eidelman O, Schlegel R, Tralka T S, Blumenthal R.pH-dependent fusion induced by vesicular stomatitis virus glycoprotein reconstituted into phospholipid vesicles[J/OL]. J Biol Chem, 1984, 259(7):4622–4628.
• [12]Sun X, Roth S L, Bialecki M A, Whittaker G R.Internalization and fusion mechanism of vesicular stomatitis virus and related rhabdoviruses[J/OL].Future Virol, 2010, 5(1):85–96. DOI:10.2217/FVL.09.72.
• [13]Mathieu M E, Grigera P R, Helenius A, Wagner R R.Folding, unfolding, and refolding of the vesicular stomatitis virus glycoprotein[J/OL]. Biochemistry,1996, 35(13):4084–4093. DOI:10.1021/bi952924i.
• [14]Ahmed M, Lyles D S. Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA polymerases I, II, and III[J/OL]. J Virol, 1998,72(10):8413–8419. DOI:10.1128/JVI. 72.10.8413-8419.1998.
• [15]Black B L, Lyles D S. Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo[J/OL]. J Virol, 1992, 66(7):4058–4064. DOI:10.1128/JVI.66.7.4058-4064.1992.
• [16]Barr J N, Whelan S P J, Wertz G W. Transcriptional control of the RNA-dependent RNA polymerase of vesicular stomatitis virus[J/OL]. Biochim Biophys.Acta, 2002, 1577(2):337–353. DOI:10.1016/s0167-4781(02)00462-1.
• [17]Iverson L E, Rose J K. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription[J/OL]. Cell, 1981, 23(2):477–484.DOI:10.1016/0092-8674(81)90143-4.
• [18]Ball L A, White C N. Order of transcription of genes of vesicular stomatitis virus[J/OL]. Proc Natl Acad Sci U S A. 1976 Feb;73(2):442-6. DOI:10.1073/pnas.73.2.442.
• [19]Villarreal L P, Breindl M, Holland J J. Determination of molar ratios of vesicular stomatitis virus induced RNA species in BHK21 cells[J/OL]. Biochemistry. 1976 Apr20;15(8):1663-7. DOI:10.1021/bi00653a012.
• [20]Lawson N D, Stillman E A, Whitt M A, Rose J K.Recombinant vesicular stomatitis viruses from DNA[J/OL]. Proc Natl Acad Sci U S A, 1995, 92(10):4477–4481. DOI:10.1073/pnas.92.10.4477.
• [21]Clarke D K, Hendry R M, Singh V, Rose J K,Seligman S J, Klug B, Kochhar S, Mac L M, Carbery B, Chen R T. Live virus vaccines based on a vesicular stomatitis virus(VSV)backbone:Standardized template with key considerations for a risk/benefit assessment[J/OL]. Vaccine, 2016, 34(51):6597–6609. DOI:10.1016/j.vaccine.2016.06.071.
• [22]Geisbert T W, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections[J/OL]. J Infect, 2011, 204Suppl 3:S1075-1081. DOI:10.1093/infdis/jir349.
• [23]卢建博，郑文铝，余云舟，叶建强，戴秋云，&刘珠果.重组水疱性口炎病毒载体病毒包装体系的建立及优化[J/OL].生物技术通讯，2018, 29(2):6. DOI:CNKI:SUN:SWTX.0.2018-02-005.
• [24]Monath T P, Nichols R, Tussey L, Scappaticci K,Pullano T G, Whiteman M D, Vasilakis N, Rossi S L,Campos R K, Azar S R, Spratt H M, Seaton B L,Archambault W T, Costecalde Y V, Moore E H,Hawks R J, Fusco J. Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile:Model for assessment of live vaccines with neurotropic potential[J/OL]. PLoS Pathog, 2022, 18(6):e1010658. DOI:10.1371/journal.ppat.1010658.
• [25]Johnson J E, Nasar F, Coleman J W, Price R E,Javadian A, Draper K, Lee M, Reilly P A, Clarke D K Hendry R M, Udem S A. Neurovirulence properties of recombinant vesicular stomatitis virus vectors in nonhuman primates[J/OL]. Virology, 2007, 360(1):36–49. DOI:10.1016/j.virol.2006.10.026.
• [26]Monath T P, Fast P E, Modjarrad K, Clarke D K,Martin B K, Fusco J, Nichols R, Heppner D G, Simon J K, Dubey S, Troth S P, Wolf J, Singh V, Coller B A, Robertson J S, Brighton Collaboration Viral Vector Vaccines Safety Working Group(V3SWG). rVSVΔGZEBOV-GP(also designated V920)recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein:Standardized template with key considerations for a risk/benefit assessment[J/OL].Vaccine:X, 2019, 1:100009. DOI:10.1016/j.jvacx.2019.100009.
• [27]Clarke D K, Hendry R M, Singh V, Rose J K,Seligman S J, Klug B, Kochhar S, Mac L M, Carbery B, Chen R T, Live virus vaccines based on a vesicular stomatitis virus(VSV)backbone:Standardized template with key considerations for a risk/benefit assessment[J/OL]. Vaccine, 2016, 34(51):6597–6609. DOI:10.1016/j.vaccine.2016.06.071.
• [28]Geisbert T W, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections[J/OL]. J Infect Dis, 2011,204 Suppl 3(Suppl 3):S1075-1081. DOI:10.1093/infdis/jir349.
• [29]Ayala-Breton C, Russell L O J, Russell S J, Peng K W. Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus[J/OL]. J. Virol, 2014, 88(15):8332–8339. DOI:10.1128/JVI.03823-13.
• [30]Abdullahi S, J?kel M, Behrend S J, Steiger K,Topping G, Krabbe T, Colombo A, Sandig V,Schiergens T S, Thasler W E, Werner J, Lichtenthaler S F, Schmid R M, Ebert O, Altomonte J. A novel chimeric oncolytic virus vector for improved safety and efficacy as a platform for the treatment of hepatocellular carcinoma[J/OL]. J Virol, 2018, 92(23):e01386-18.DOI:10.1128/JVI.01386-18.
• [31]Huttner A, Dayer J-A, Yerly S, Combescure C,Auderset F, Desmeules J, Eickmann M, Finckh A,Goncalves A R, Hooper J W, Kaya G, Kr?hling V,Kwilas S, Lema?tre B, Matthey A, Silvera P, Becker S, Fast P E, Moorthy V, Kieny M P, Kaiser L,Siegrist C A. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine:a randomised double-blind, placebo-controlled phase 1/2trial[J/OL]. Lancet Infect Dis, 2015, 15(10):1156–1166. DOI:10.1016/S1473-3099(15)00154-1.
• [32]Kong X-W, Zhang X, Bu G-L, Xu H Q, Kang Y F,Sun C, Zhu Q Y, Ma R B, Liu Z, Zeng Y X, Zeng M S, Hu Z L. Vesicular stomatitis virus-based epstein-barr virus vaccines elicit strong protective immune responses[J/OL]. J Virol, 2022, 96(9):e0033622. DOI:10.1128/jvi.00336-22.
• [33]Fuchs J D, Frank I, Elizaga M L, Allen M, Frahm N,Kochar N, Li S, Edupuganti S, Kalams S A, Tomaras G D, Sheets R, Pensiero M, Tremblay M A, Higgins T J, Latham T, Egan M A, Clarke D K, Eldridge J H,Mulligan M, Rouphael N, Estep S, Rybczyk K,Dunbar D, Buchbinder S, Wagner T, Isbell R,Chinnell V, Bae J, Escamilla G, Tseng J, Fair R,Ramirez S, Broder G, Briesemeister L, Ferrara A.First-in-Human evaluation of the safety and immunogenicity of a recombinant vesicular stomatitis virus human immunodeficiency virus-1 gag vaccine(HVTN 090)[J/OL]. Open Forum Infect Dis, 2015, 2(3):ofv082. DOI:10.1093/ofid/ofv082.
• [34]Wollmann G, Drokhlyansky E, Davis J N, Cepko C,van den Pol, A. N. Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors[J/OL]. J Virol,2015, 89(13):6711–6724. DOI:10.1128/JVI.00709-15.
• [35]Muik A, Stubbert L J, Jahedi R Z, Gei B Y, Kimpel J,Dold C, Tober R, Volk A, Klein S, Dietrich U,Yadollahi B, Falls T, Miletic H, Stojdl D, Bell J C,von Laer D. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity,and enhance oncolytic potency[J/OL]. Cancer Res,2014, 74(13):3567–3578. DOI:10.1158/0008-5472.CAN-13-3306.
• [36]Janelle V, Brassard F, Lapierre P, Lamarre A,Poliquin L. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity:potential for oncolytic virotherapy[J/OL]. J Virol, 2011, 85(13):6513–6520. DOI:10.1128/JVI.02484-10.
• [37]Janelle V, Langlois M-P, Lapierre P, Charpentier T,Poliquin L, Lamarre A. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control[J/OL]. Mol Ther, 2014, 22(6):1198–1210.DOI:10.1038/mt.2014.34.
• [38]Hoffmann M, Wu Y J, Gerber M, Berger-Rentsch M,Heimrich B, Schwemmle M, Zimmer G. Fusion-active glycoprotein G mediates the cytotoxicity of vesicular stomatitis virus M mutants lacking host shut-off activity[J/OL]. J Gen Virol, 2010, 91(Pt 11):2782–2793.DOI:10.1099/vir.0.023978-0.
• [39]Roberts A, Buonocore L, Price R, Forman J, Rose J K. Attenuated vesicular stomatitis viruses as vaccine vectors[J/OL]. J Virol, 1999, 73(5):3723–3732.DOI:10.1128/JVI.73.5.3723-3732.1999.
• [40]Marquis K A, Becker R L, Weiss A N, Morris M C,Ferran M C. The VSV matrix protein inhibits NF-κB and the interferon response independently in mouse L929cells[J/OL]. Virology, 2020, 548:117–123. DOI:10.1016/j.virol.2020.06.013.
• [41]Varble A J, Ried C D, Hammond W J, Marquis K A,Woodruff M C, Ferran M C. The vesicular stomatitis virus matrix protein inhibits NF-κB activation in mouse L929 cells[J/OL]. Virology, 2016, 499:99–104.DOI:10.1016/j.virol.2016.09.009.
• [42]Ahmed M, McKenzie M O, Puckett S, Hojnacki M,Poliquin L, Lyles D S. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis[J/OL]. J Virol, 2003,77(8):4646–4657. DOI:10.1128/jvi. 77.8.4646-4657.2003.
• [43]Kim G N, Kang C Y. Matrix protein of VSV New Jersey serotype containing methionine to arginine substitutions at positions 48 and 51 allows near-normal host cell gene expression[J]. Virology, 2007, 357(1):41–53. DOI:10.1016/j.virol.2006.07.022.
• [44]Morris M C, Russell T M, Lyman C A, Wong W K,Broderick G, Ferran M C. Computational prediction of intracellular targets of wild-type or mutant vesicular stomatitis matrix protein, China[J/OL]. PLoS One,2022, 17(2):e0263065. DOI:10.1371/journal.pone.0263065.
• [45]Vanden Pol A N, Davis J N. Highly attenuated recombinant vesicular stomatitis virus VSV-12’GFP displays immunogenic and oncolytic activity[J/OL]. J Virol, 2013, 87(2):1019–1034. DOI:10.1128/JVI.01106-12.
• [46]Flanagan E B, Schoeb T R, Wertz G W. Vesicular stomatitis viruses with rearranged genomes have altered invasiveness and neuropathogenesis in mice[J/OL]. J Virol, 2003, 77(10):5740–5748. DOI:10.1128/jvi.77.10.5740-5748.2003.
• [47]Rouxel R N, Tafalla C, Mérour E, Leal E, Biacchesi S, Brémont M. Attenuated infectious hematopoietic necrosis virus with rearranged gene order as potential vaccine[J/OL]. J Virol, 2016, 90(23):10857–10866.DOI:10.1128/JVI.01024-16.
• [48]Wang T, Wang L, Han Y, Pan L, Yang J, Sun M,Zhou P, Sun Y, Bi Y, Qiu HJ. Adaptation of African swine fever virus to HEK293T cells[J/OL].Transbound Emerg Dis. 2021;68(5):2853-2866. DOI:10.1111/tbed.14242.
• [49]Tazawa H, Hasei J, Yano S, Kagawa S, Ozaki T,Fujiwara T. Bone and soft-tissue sarcoma:a new target for telomerase-specific oncolytic virotherapy[J/OL].Cancers(Basel). 2020;12(2):478. DOI:10.3390/cancers12020478.
• [50]Su YC, Huang YF, Wu YW, Chen HF, Wu YH, Hsu CC, Hsu YC, Lee JC. MicroRNA-155 inhibits dengue virus replication by inducing heme oxygenase-1-mediated antiviral interferon responses[J/OL]. FASEB J. 2020Jun;34(6):7283-7294. DOI:10.1096/fj.201902878R.
• [51]Novella IS, Presloid JB, Zhou T, Smith-Tsurkan SD,Ebendick-Corpus BE, Dutta RN, Lust KL, Wilke CO.Genomic evolution of vesicular stomatitis virus strains with differences in adaptability[J/OL]. J Virol. 2010May;84(10):4960-8. DOI:10.1128/JVI.00710-09.
• [52]Fathi A, Dahlke C, Addo MM. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens[J/OL]. Hum Vaccin Immunother.2019; 15(10):2269-2285. DOI:10.1080/21645515.2019.1649532.
• [53]Qiu X, Fernando L, Alimonti J B, Melito P L,Feldmann F, Dick D, Str?her U, Feldmann H, Jones S M. Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses, China[J/OL].PloS One, 2009, 4(5):e5547. DOI:10.1371/journal.pone.0005547.
• [54]Agnandji S T, Huttner A, Zinser M E, Njuguna P,Dahlke C, Fernandes J F, Yerly S, Dayer J A,Kraehling V, Kasonta R, Adegnika A A, Altfeld M,Auderset F, Bache E B, Biedenkopf N, Borregaard S,Brosnahan J S, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling S K, Finckh A, Goncalves A R, Grobusch M P, Hooper J, Jambrecina A,Kabwende A L, Kaya G, Kimani D, Lell B, Lema?tre B, Lohse A W, Massinga-Loembe M, Matthey A,Mordmüller B, Nolting A, Ogwang C, Ramharter M,Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl F R, Staines H M, Strecker T, Stubbe H C, Tsofa B,Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S,Becker S, Kieny M P, Bejon P, Kremsner P. G, Addo M M, Siegrist C A. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe[J/OL]. N Engl J Med,2016, 374(17):1647–1660. DOI:10.1056/NEJMoa1502924.
• [55]Regules J A, Beigel J H, Paolino K M, Voell J,Castellano A R, Hu Z, Mu?oz P, Moon J E, Ruck R C, Bennett J W, Twomey P S, Gutiérrez R L, Remich S A, Hack H R, Wisniewski M L, Josleyn M D,Kwilas S A, Van Deusen N, Mbaya O T, Zhou Y,Stanley D A, Jing W, Smith K S, Shi M, Ledgerwood J E, Graham B S, Sullivan N J, Jagodzinski L L, Peel S A, Alimonti J B, Hooper J W, Silvera P M, Martin B K, Monath T P, Ramsey W J, Link C J, Lane H C,Michael N L, Davey R T, Thomas S J. A recombinant vesicular stomatitis virus Ebola vaccine[J/OL]. N Engl J Med, 2017, 376(4):330–341. DOI:10.1056/NEJMoa1414216.
• [56]Dahlke C, Kasonta R, Lunemann S, Kr?hling V,Zinser M E, Biedenkopf N, Fehling S K, Ly M L,Rechtien A, Stubbe H C, Olearo F, Borregaard S,Jambrecina A, Stahl F, Strecker T, Eickmann M,Lütgehetmann M, Spohn M, Schmiedel S, Lohse A W, Becker S, Addo M M. Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization[J/OL]. EBio Medicine, 2017, 19:107–118. DOI:10.1016/j.ebiom.2017.03.045.
• [57]Agnandji S T, Fernandes J F, Bache E B, Obiang Mba R M, Brosnahan J S, Kabwende L, Pitzinger P,Staarink P, Massinga-Loembe M, Kr?hling V,Biedenkopf N, Fehling S K, Strecker T, Clark D J,Staines H M, Hooper J W, Silvera P, Moorthy V,Kieny M P, Adegnika A A, Grobusch M P, Becker S,Ramharter M, Mordmüller B, Lell B, Krishna S,Kremsner P G. Safety and immunogenicity of rVSVΔGZEBOV-GP Ebola vaccine in adults and children in Lambaréné，Gabon:A phase I randomised trial[J/OL].PLoS Med, 2017, 14(10):e1002402. DOI:10.1371/journal.pmed.1002402.
• [58]Marzi A, Reynolds P, Mercado-Hernandez R, Callison J, Feldmann F, Rosenke R, Thomas T, Scott D P,Hanley P W, Haddock E, Feldmann H. Single lowdose VSV-EBOV vaccination protects cynomolgus macaques from lethal Ebola challenge[J/OL]. EBio Medicine, 2019, 49:223–231. DOI:10.1016/j.ebiom.2019.09.055.
• [59]Feldmann H, Jones S M, Daddario-DiCaprio K M,Geisbert J B, Str?her U, Grolla A, Bray M, Fritz E A,Fernando L, Feldmann F, Hensley L E, Geisbert T W.Effective post-exposure treatment of Ebola infection[J/OL]. PLoS Pathog, 2007, 3(1):e2. DOI:10.1371/journal.ppat.0030002.
• [60]Marzi A, Feldmann F, Geisbert T W, Feldmann H,Safronetz D. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses[J/OL]. Emerg Infect Dis, 2015, 21(2):305–307. DOI:10.3201/eid2102.141649.
• [61]Mire C E, Miller A D, Carville A, Westmoreland S V,Geisbert J B, Mansfield K G, Feldmann H, Hensley L E, Geisbert T W. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates[J/OL].PLoS Negl Trop Dis, 2012, 6(3):e1567. DOI:10.1371/journal.pntd.0001567.
• [62]McWilliams I L, Kielczewski J L, Ireland D D C,Sykes J S, Lewkowicz A P, Konduru K, Xu B C,Chan C C, Caspi R R, Manangeeswaran M, Verthelyi D. Pseudovirus rVSVΔG-ZEBOV-GP infects neurons in retina and CNS, causing apoptosis and neurodegeneration in neonatal mice[J/OL]. Cell Rep,2019, 26(7):1718-1726. e4. DOI:10.1016/j.celrep.2019.01.069.
• [63]De Wit E, Marzi A, Bushmaker T, Brining D, Scott D, Richt J. A, Geisbert T W, Feldmann H. Safety of recombinant VSV-Ebola virus vaccine vector in pigs[J/OL]. Emerg Infect Dis, 2015, 21(4):702–704. DOI:10.3201/eid2104.142012.
• [64]Morozov I, Monath T P, Meekins D A, Trujillo J D,Sunwoo S Y, Urbaniak K, Kim I J, Narayanan S K,Indran S V, Ma W, Wilson W C, O’Connor C, Dubey S, Troth S P, Coller B A, Nichols R, Martin B K,Feldmann H, Richt J A. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission[J/OL]. Emerg Microbes Infect, 2021, 10(1):651–663. DOI:10.1080/22221751.2021.1903343.
• [65]Halperin S A, Arribas J R, Rupp R, Andrews C P,Chu L, Das R, Simon J K, Onorato M T, Liu K,Martin J, Helmond F A. Six-Month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a Phase 3 double-blind,placebo-controlled randomized study in healthy adults[J/OL]. J. Infect. Dis, 2017, 215(12):1789–1798.DOI:10.1093/infdis/jix189.
• [66]Henao-Restrepo A M, Camacho A, Longini I M,Watson C H, Edmunds W J, Egger M, Carroll M W,Dean N E, Diatta I, Doumbia M, Draguez B,Duraffour S, Enwere G, Grais R, Gunther S, Gsell P S, Hossmann S, Watle S V, KondéM K, Ké?ta S,Kone S, Kuisma E, Levine M M, Mandal S, Mauget T, Norheim G, Riveros X, Soumah A, Trelle S,Vicari A S, R?ttingen J A, Kieny M P. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease:final results from the Guinea ring vaccination, open-label, cluster-randomised trial(Ebola?a Suffit!)[J/OL]. Lancet Lond. Engl, 2017, 389(10068):505–518. DOI:10.1016/S0140-6736(16)32621-6.
• [67]Cooper D, Wright K J, Calderon P C, Guo M, Nasar F, Johnson J E, Coleman J W, Lee M, Kotash C,Yurgelonis I, Natuk R J, Hendry R M, Udem S A,Clarke D K. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1va